1. Peptides
  2. Cibinetide

Cibinetide (Synonyms: ARA290)

Cat. No.: HY-P0168 Purity: 99.81%
Handling Instructions

Cibinetide (ARA290) is an EPO-derivative, acting as a specific agonist of erythropoietin/CD131 heteroreceptor, and used for neurological disease treatment.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Cibinetide Chemical Structure

Cibinetide Chemical Structure

CAS No. : 1208243-50-8

Size Price Stock Quantity
1 mg USD 250 In-stock
Estimated Time of Arrival: December 31
5 mg USD 750 In-stock
Estimated Time of Arrival: December 31
10 mg USD 1250 In-stock
Estimated Time of Arrival: December 31
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 2 publication(s) in Google Scholar

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Cibinetide

    Cibinetide purchased from MCE. Usage Cited in: Toxicol In Vitro. 2020 Aug;66:104864.

    Representative photomicrographs demonstrate the results of the TUNEL assay. Alterations in apoptotic cells are assessed using the ratio of green fluorescence. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Cibinetide (ARA290) is an EPO-derivative, acting as a specific agonist of erythropoietin/CD131 heteroreceptor, and used for neurological disease treatment.

    In Vitro

    Cibinetide (ARA290) enhances the proliferation, migration, and resistance to H2O2-induced apoptosis of endothelial colony-forming cells (ECFCs)[1]. Cibinetide (ARA290) is an EPO-analog peptide without hematopoietic side-effects but may have neurotrophic and antidepressant effects[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    After ECFC transplantation to mice with CLI, a single Cibinetide (ARA290) injection enhances the ischemic/non-ischemic ratio of hindlimb blood flow and capillary density after 28 days and the homing of radiolabeled transplanted cells to the ischemic leg 4 h after transplantation[1]. Cibinetide (ARA290; 30 μg/kg, s.c.) prevents progressive worsening of glucose control without affecting body weight of rats. Cibinetide significantly decreases glucose AUCs in IPGTT in GK rats[2]. Low-dosage Cibinetide (35 μg/kg, i.p.) treatment only slightly attenuates the EAE severity in rats. Cibinetide-treating group (70 μg/kg, i.p.) significantly delays the onset, decreases the neurologic severity and shortens the duration of EAE in a dose-dependent way[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Molecular Weight

    1257.31

    Formula

    C₅₁H₈₄N₁₆O₂₁

    CAS No.
    Sequence Shortening

    {Glp}-EQLERALNSS

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -80°C 2 years
    -20°C 1 year
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 34 mg/mL (27.04 mM)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 0.7953 mL 3.9767 mL 7.9535 mL
    5 mM 0.1591 mL 0.7953 mL 1.5907 mL
    10 mM 0.0795 mL 0.3977 mL 0.7953 mL
    *Please refer to the solubility information to select the appropriate solvent.
    References
    Animal Administration
    [2]

    Diabetic Goto-Kakizaki (GK) rats, originating from Wistar rats, are bred in our department. Normal Wistar (W) rats are used as nondiabetic controls. All animals are about six weeks old and with body weights 100 to 150 g when treatment is initiated. They are kept at 22°C on a reversed 12-h light-dark cycle with free access to food, except when fasted overnight as noted below. Rats are treated over 4 wks with Cibinetide by a once daily subcutaneous (s.c.) injection at a dose of 30 μg/kg body weight or PBS. Blood samples for determination of glucose are taken after a small tail incision and analyzed every week before morning s.c. injection of either Cibinetide or placebo. During the experimental period, body weights are measured weekly.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email address *

    Phone number *

     

    Organization name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cibinetide
    Cat. No.:
    HY-P0168
    Quantity:
    MCE Japan Authorized Agent: